Navigation Links
AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
Date:12/8/2009

WILMINGTON, Del., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Prescriptions also now will be mailed to patients' homes or physician's offices under the changes to the AZ&Me(TM) Prescription Savings program for people with Medicare Part D. The changes will take effect Jan. 1, 2010.

"These changes will better serve Medicare Part D enrollees by making it easier for them to access the medicines they need," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP. "This prescription savings program and these latest improvements reflect our ongoing commitment to patient health."

Currently, patients enrolled in the program fill their AstraZeneca prescriptions at retail pharmacies and have a co-pay of between $15 and $25, depending on their qualifying income. The elimination of a co-pay will save approximately 30,000 patients enrolled in the program a total of $3 million each year.

Program Details

Eligible patients can enroll in the AZ&Me(TM) Prescription Savings program for people with Medicare Part D at any time in the calendar year, but must meet program requirements in order to start utilizing the benefit.

The AZ&Me(TM) Prescription Savings program for people with Medicare Part D is one of three distinct prescription savings programs in the AZ&Me Prescription Savings Program suite. Other AZ&Me Prescription Savings Programs include a plan for individuals without insurance and one for healthcare facilities.

To learn if you qualify for the AZ&Me Prescription Savings Programs, please visit www.AZandMe.com or call 1-800-AZandMe. Program specialists are available Monday through Friday between the hours of 9:00 AM and 5:00 PM EST.

Other prescription savings programs are available regardless of which medications your doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4PPA-NOW (1-888-477-2669).

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.

SOURCE AstraZeneca


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
2. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
3. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
4. Jubilant Enters Research Collaboration With AstraZeneca
5. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
6. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
9. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
10. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
11. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):